Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,962,521
  • Shares Outstanding, K 182,309
  • Annual Sales, $ 152,920 K
  • Annual Income, $ -444,440 K
  • 60-Month Beta 1.51
  • Price/Sales 18.97
  • Price/Cash Flow N/A
  • Price/Book 2.98
Trade NKTR with:

Options Overview

Details
  • Implied Volatility 112.39%
  • Historical Volatility 30.71%
  • IV Percentile 85%
  • IV Rank 65.30%
  • IV High 153.15% on 10/14/20
  • IV Low 35.66% on 06/24/21
  • Put/Call Vol Ratio 0.44
  • Today's Volume 95
  • Volume Avg (30-Day) 449
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 22,171
  • Open Int (30-Day) 21,778

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.72
  • Number of Estimates 8
  • High Estimate -0.67
  • Low Estimate -0.76
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.75 +1.97%
on 07/19/21
17.73 -9.41%
on 07/01/21
-1.35 (-7.75%)
since 06/29/21
3-Month
15.75 +1.97%
on 07/19/21
20.25 -20.69%
on 05/10/21
-4.03 (-20.06%)
since 04/29/21
52-Week
15.40 +4.32%
on 10/29/20
26.75 -39.96%
on 02/17/21
-6.66 (-29.31%)
since 07/29/20

Most Recent Stories

More News
What's in Store for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

IRWD : 13.16 (-1.86%)
PRGO : 47.89 (+1.16%)
NKTR : 16.06 (-1.17%)
PETQ : 35.52 (-1.00%)
Nektar to Announce Financial Results for the Second Quarter 2021 on Thursday, August 5, 2021, After Close of U.S.-Based Financial Markets

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2021 on Thursday, August 5, 2021, after the close of U.S.-based financial markets. Howard...

NKTR : 16.06 (-1.17%)
Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has appointed , M.D., Ph.D., as Senior Vice President and Chief Medical Officer (CMO). In his role as CMO, Dr. Nuyten will have...

NKTR : 16.06 (-1.17%)
Pain Relief Therapeutics Market 2021 Opportunity Assessment, Business Opportunities, Top Industry Players, Trend and Growth to 2027

ABT : 121.09 (+0.47%)
ACRX : 1.2000 (unch)
ACOR : 3.95 (+1.54%)
AXSM : 50.57 (-4.24%)
BAYRY : 15.1300 (+1.61%)
BDRFF : 119.7000 (unch)
BDSI : 3.76 (-0.53%)
BMY : 68.15 (-0.84%)
COLL : 25.00 (-0.60%)
DEPO : 7.30 (+1.67%)
DRRX : 1.5100 (+2.72%)
EGLT : 0.0315 (-63.37%)
LLY : 245.33 (-0.48%)
FLXN : 5.87 (-5.78%)
GLPG : 60.54 (-0.87%)
HRTX : 12.32 (-2.76%)
KMPH : 10.31 (-6.19%)
MRK : 76.93 (-1.79%)
MESO : 7.06 (+1.73%)
NKTR : 16.06 (-1.17%)
NVS : 92.19 (+0.33%)
ORXOY : 4.4499 (-1.55%)
PFE : 42.79 (-1.52%)
REGN : 583.13 (-0.56%)
VRX.TO : 30.80 (-3.33%)
Exelixis (EXEL) & Bristol Myers Team Up for Genitourinary Cancers

Exelixis (EXEL) collaborates with Bristol Myers to evaluate its next-generation tyrosine kinase inhibitor in combination with immuno-oncology therapies in advanced solid tumors.

BMY : 68.15 (-0.84%)
EXEL : 16.86 (-1.63%)
NKTR : 16.06 (-1.17%)
RGEN : 241.00 (+2.43%)
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors

Exelixis, Inc. (Nasdaq: EXEL) today announced a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company (NYSE: BMY) for STELLAR-002, a new phase 1b trial evaluating XL092 in...

BMY : 68.15 (-0.84%)
NKTR : 16.06 (-1.17%)
EXEL : 16.86 (-1.63%)
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference

/PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 42 Annual Global Healthcare Conference on at...

NKTR : 16.06 (-1.17%)
US Pain Relief Therapeutics Market Share 2021 : Growth Opportunities with Covid-19 Impact Analysis, Business Structure with Top Key Players Size, Development Plans and Challenges Forecast to 2027

The rising prevalence of chronic diseases such as a variety of cancers, osteoarthritis, stomach ulcer, chronic arthritis and diabetes are major key factor which drives the Global Pain Relief Therapeutics...

ABT : 121.09 (+0.47%)
ACRX : 1.2000 (unch)
ACOR : 3.95 (+1.54%)
AXSM : 50.57 (-4.24%)
BAYRY : 15.1300 (+1.61%)
BDRFF : 119.7000 (unch)
BDSI : 3.76 (-0.53%)
BMY : 68.15 (-0.84%)
COLL : 25.00 (-0.60%)
DEPO : 7.30 (+1.67%)
DRRX : 1.5100 (+2.72%)
EGLT : 0.0315 (-63.37%)
LLY : 245.33 (-0.48%)
FLXN : 5.87 (-5.78%)
GLPG : 60.54 (-0.87%)
HRTX : 12.32 (-2.76%)
KMPH : 10.31 (-6.19%)
MRK : 76.93 (-1.79%)
MESO : 7.06 (+1.73%)
NKTR : 16.06 (-1.17%)
NVS : 92.19 (+0.33%)
ORXOY : 4.4499 (-1.55%)
PFE : 42.79 (-1.52%)
REGN : 583.13 (-0.56%)
VRX.TO : 30.80 (-3.33%)
Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity

, /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in the describing NKTR-358, a first-in-class, composition of stable PEG conjugates of native...

NKTR : 16.06 (-1.17%)
Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC)

, /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data from its second major immuno-oncology cytokine program, NKTR-255, in the . NKTR-255 is a novel...

NKTR : 16.06 (-1.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists...

See More

Key Turning Points

3rd Resistance Point 16.89
2nd Resistance Point 16.69
1st Resistance Point 16.38
Last Price 16.06
1st Support Level 15.87
2nd Support Level 15.67
3rd Support Level 15.36

See More

52-Week High 26.75
Fibonacci 61.8% 22.41
Fibonacci 50% 21.07
Fibonacci 38.2% 19.73
Last Price 16.06
52-Week Low 15.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar